Loading the company…
Loading the company…
Families: Kidney stone management, Hysterectomy, hysteroscopy & ablation, Ear tubes & middle ear surgery, Cholecystectomy & appendectomy.
All companies · Product and company coverage
In the last ten years FDA made 1 decision for Gyrus Acmi (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 2 procedure families, the most in 2024 (1). The latest was on 2024-03-25.
| Family | Decisions on record |
|---|---|
| Kidney stone management | 1 |
| Hysterectomy, hysteroscopy & ablation | 1 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2024-03-25 | 510(k) | K233275 | RenaFlex Single-use Flexible Ureteroscope (SUURF-V Standard); RenaFlex Single-use Flexible Ureteroscope (SUURF-VR Reverse); Video System Center for Single-use Endoscopes (CV-S1) |
| 2009-09-29 | 510(k) | K092278 | GYRUS ACMI INVISIO DIGITAL HYSTEROSCOPE, MODEL IDH-4 |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Gyrus Acmi.
In 2025, Gyrus Acmi reported engagement with 64 surgeons and other clinicians in the states MedaRep covers, worth $107K in consulting, speaking, meals and travel for its device products, the most in Massachusetts ($55K to 24). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Massachusetts ($55K, 24 engaged), New York ($11K, 5 engaged), Pennsylvania ($8,409, 2 engaged), Florida ($7,680, 1 engaged), Rhode Island ($5,662, 2 engaged).